Details of the Drug Combination

General Information of Drug Combination (ID: DCI5ZDI)

Drug Combination Name
RTB101 10-hydroxycamptothecin
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs RTB101   DM62QTW 10-hydroxycamptothecin   DM9WLN4
Small molecular drug Small molecular drug
High-throughput Screening Result Testing Cell Line: NCIH2122
Zero Interaction Potency (ZIP) Score: 4.8
Bliss Independence Score: 4.81
Loewe Additivity Score: 7.83
LHighest Single Agent (HSA) Score: 11.13

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of RTB101
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Phase 3 [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
RTB101 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
CREB-regulated transcription coactivator 1 (TORC1) TT4GO0F CRTC1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of 10-hydroxycamptothecin
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [4]
10-hydroxycamptothecin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
10-hydroxycamptothecin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [6]
------------------------------------------------------------------------------------
10-hydroxycamptothecin Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Response To Substance [7]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Affects Response To Substance [8]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Response To Substance [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCEI2EO ES2 Investigative [9]
Breast and ovarian cancer syndrome DC70T79 UWB1289+BRCA1 Investigative [10]
Breast carcinoma DCO7IGG KPL1 Investigative [10]
Breast carcinoma DCAQ2G2 OCUBM Investigative [10]
Carcinoma DCANIEV OV90 Investigative [10]
Carcinoma DCLV1F4 EFM192B Investigative [10]
Carcinoma DC1OJR8 MDAMB436 Investigative [10]
Colon adenocarcinoma DCQF1SQ LOVO Investigative [10]
Colon carcinoma DCIUOPX RKO Investigative [10]
Invasive ductal carcinoma DCVV2VP T-47D Investigative [10]
Adenocarcinoma DCK4H65 CAOV3 Investigative [1]
Adenocarcinoma DCDER3M A427 Investigative [1]
Adenocarcinoma DCU89D9 NCIH1650 Investigative [1]
Adenocarcinoma DC61SB2 NCIH23 Investigative [1]
Adenocarcinoma DCNBLJJ NCIH520 Investigative [1]
Adenocarcinoma DCJS2P9 COLO320DM Investigative [1]
Adenocarcinoma DC195ZG DLD1 Investigative [1]
Adenocarcinoma DC5FL23 HCT116 Investigative [1]
Adenocarcinoma DC1TSGF HT29 Investigative [1]
Adenocarcinoma DC25U1I SW-620 Investigative [1]
Germ cell tumour DC0QG2Q PA1 Investigative [1]
Large cell lung carcinoma DCA4PKC NCI-H460 Investigative [1]
Malignant melanoma DC73RMG A375 Investigative [1]
Malignant melanoma DCGQTR9 HT144 Investigative [1]
Malignant melanoma DCBB4AQ SKMEL30 Investigative [1]
Malignant melanoma DC4VG6Z UACC62 Investigative [1]
Malignant melanoma DCVDE1Y RPMI7951 Investigative [1]
Mesothelioma DC78ZRE MSTO Investigative [1]
Non small cell carcinoma DCBLW49 SKMES1 Investigative [1]
Ovarian endometrioid adenocarcinoma DCUHBEJ A2780 Investigative [1]
Ovarian serous cystadenocarcinoma DCJGGBO SK-OV-3 Investigative [1]
Prostate carcinoma DCQJMLK LNCAP Investigative [1]
Prostate carcinoma DCHJCX9 VCAP Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 33 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
4 Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol. 1998 Apr;12(4):793-804.
5 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
6 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
7 siRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs. Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):450-6. doi: 10.1111/j.1440-1681.2007.04593.x.
8 Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11636-41. doi: 10.1073/pnas.1934692100. Epub 2003 Sep 16.
9 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
10 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.